Tsontcho Ianchulev Biography and Net Worth

CEO of Hyperion DeFi

Dr. Ianchulev has been serving as our Chief Executive Officer, Chief Medical Officer and a member of our Board of Directors since March 2014. From 2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical, Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (NYSE: DNA, before going private in 2009), Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis. Dr. Ianchulev currently serves as a director of the ASCRS Foundation, and is a member of the Board of Directors of Iantrek, Inc. and AEye, Inc. He was formerly chairman of the board of directors of ianTECH from 2014 until its acquisition by Carl Zeiss Meditec AG (ETR: AFX) in 2019. Dr. Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.

What is Tsontcho Ianchulev's net worth?: The estimated net worth of Tsontcho Ianchulev is at least $16.44 thousand as of May 1st, 2023. Dr. Ianchulev owns 4,140 shares of Hyperion DeFi stock worth more than $16,436 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Ianchulev may own. Additionally, Dr. Ianchulev receives a salary of $167,500.00 as CEO at Hyperion DeFi. Learn More about Tsontcho Ianchulev's net worth.
How old is Tsontcho Ianchulev?: Dr. Ianchulev is currently 50 years old. There are 3 older executives and no younger executives at Hyperion DeFi. The oldest executive at Hyperion DeFi is Mr. John P. Gandolfo CPA, CFO & Secretary, who is 63 years old. Learn More on Tsontcho Ianchulev's age.
What is Tsontcho Ianchulev's salary?: As the CEO of Hyperion DeFi, Inc., Dr. Ianchulev earns $167,500.00 per year. There are 3 executives that earn more than Dr. Ianchulev. The highest earning executive at Hyperion DeFi is Mr. Michael M. Rowe, CEO & Director, who commands a salary of $775,470.00 per year. Learn More on Tsontcho Ianchulev's salary.
How do I contact Tsontcho Ianchulev?: The corporate mailing address for Dr. Ianchulev and other Hyperion DeFi executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Hyperion DeFi can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Tsontcho Ianchulev's contact information.
Has Tsontcho Ianchulev been buying or selling shares of Hyperion DeFi?: Tsontcho Ianchulev has not been actively trading shares of Hyperion DeFi during the last ninety days. Most recently, Tsontcho Ianchulev sold 1,125 shares of the business's stock in a transaction on Monday, May 1st. The shares were sold at an average price of $440.00, for a transaction totalling $495,000.00. Following the completion of the sale, the director now directly owns 4,140 shares of the company's stock, valued at $1,821,600. Learn More on Tsontcho Ianchulev's trading history.
Who are Hyperion DeFi's active insiders?: Hyperion DeFi's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Hyperion DeFi's active insiders.

Tsontcho Ianchulev Insider Trading History at Hyperion DeFi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2023	Sell	1,125	$440.00	$495,000.00	4,140
4/27/2023	Sell	750	$400.00	$300,000.00	5,265
4/14/2023	Sell	500	$360.00	$180,000.00	6,015
4/11/2023	Sell	500	$320.00	$160,000.00	6,515
3/31/2023	Sell	500	$280.00	$140,000.00	7,015
11/3/2021	Buy	375	$323.20	$121,200.00
3/24/2020	Buy	1,030	$181.60	$187,048.00	6,358
7/11/2019	Buy	2,922	$222.40	$649,852.80
6/28/2018	Buy	75	$530.40	$39,780.00

Tsontcho Ianchulev Buying and Selling Activity at Hyperion DeFi

Hyperion DeFi Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $3.97

$3.50

$4.09

50 Day Range

MA: $6.70

$3.61

$11.83

2 Week Range

Now: $3.97

$0.85

$17.99

Volume

408,169 shs

Average Volume

328,192 shs

Market Capitalization

$32.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Tsontcho Ianchulev Biography and Net Worth

What is Tsontcho Ianchulev's net worth?

How old is Tsontcho Ianchulev?

What is Tsontcho Ianchulev's salary?

How do I contact Tsontcho Ianchulev?

Has Tsontcho Ianchulev been buying or selling shares of Hyperion DeFi?

Who are Hyperion DeFi's active insiders?